NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt

NRX Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.74

Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.
Cash and equivalents $1.3M as of March 31, 2024; additional $3.3M from equity post-quarter.
Signed non-binding term sheet for $7.5M debt to replace toxic debt, with potential total up to $30M.
Plans to file NDA for NRX-101 in bipolar depression with akathisia risk and for IV ketamine (HTX-100) by July 2024.
Hope Therapeutics spinout planned; term sheets received from anchor investors for $60M investment.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NRX Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2024.

Period: quarter ended March 31, 2024
Result: reported results

Exact text from the filing

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NRX Pharmaceuticals, Inc. reported financial results for first quarter ending March 31, 2024.

Period: first quarter ending March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ending March 31, 2024

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.